Low-Dose Oral Sirolimus and the Risk of Menstrual-Cycle Disturbances and Ovarian Cysts: Analysis of the Randomized Controlled SUISSE ADPKD Trial

Sirolimus has been approved for clinical use in non proliferative and proliferative disorders. It inhibits the mammalian target of rapamycin (mTOR) signaling pathway which is also known to regulate ovarian morphology and function. Preliminary observational data suggest the potential for ovarian toxi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Braun, Matthias, Young, James, Reiner, Cäcilia S., Poster, Diane, Krauer, Fabienne, Kistler, Andreas D., Kristanto, Paulus, Wang, Xueqi, Liu, Yang, Loffing, Johannes, Andreisek, Gustav, von Eckardstein, Arnold, Senn, Oliver, Wüthrich, Rudolf P., Serra, Andreas L.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2012
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3468602/
https://ncbi.nlm.nih.gov/pubmed/23071528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0045868
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados